[Skip to Content]
[Skip to Content Landing]
November 5, 1955


Author Affiliations

Bethesda, Md.; Baltimore, R.; Bethesda, Md.

From the U. S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, National Microbiological Institute, Laboratory of Infectious Diseases, (Drs. Huebner, Bell, Rowe, Suskind, and Paffenbarger and Miss Hartley) and the Department of Microbiology, School of Hygiene and Public Health, the Johns Hopkins University (Dr. Ward).

JAMA. 1955;159(10):986-989. doi:10.1001/jama.1955.02960270006002

It has been shown that adenoidal-pharyngeal-conjunctival (APC) viruses are responsible for certain hitherto undifferentiated respiratory illnesses and that they have been associated with certain external diseases of the eye.1 These viruses produce neutralizing antibodies in human serum.1b Nine human and two simian adenoidal-pharyngeal-conjunctival virus serotypes have been delineated to date.2 When types 1, 3, 4, and 5 are swabbed on the conjunctivas of susceptible volunteers, they regularly produce a moderately severe, self-limited catarrhal conjunctivitis, together with systemic symptoms similar to those of pharyngoconjunctival fever. Volunteers having specific serum antibodies are resistant to the disease.3 This report describes initial studies with volunteers, studies designed to determine the ability of a formaldehyde-inactivated and a heat-in-activated type 3 APC virus vaccine to (a) produce specific neutralizing antibodies in the serum and (b) to prevent or modify artificially induced infection and disease.


Preparation of Vaccines.—  The J.

First Page Preview View Large
First page PDF preview
First page PDF preview